Welcome to Innovate Biopharmaceuticals

Therapies Bringing Freedom to Life

Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases with unmet needs. Our pipeline includes drug candidates for celiac disease, NASH, Crohn’s, and ulcerative colitis. Innovate is led by a strong management team with extensive drug development experience and a history of bringing novel therapeutics to market. All global rights to the products, which are backed by more than 150 patents worldwide, are owned by the company.


Innovate is currently developing three clinical stage assets:

  • INN-202 entering Phase 3 for the treatment of celiac disease (CeD) with Fast Track designation
  • INN-217 entering Phase 1/2 for nonalcoholic steatohepatitis (NASH) alone and/or in combination with other agents
  • INN-289 entering Phase 1 for a subset of Crohn’s disease (CD)
  • INN-108 entering Phase 2 for inflammatory bowel disorders, mild to moderate ulcerative colitis (UC), and a GI orphan disease in a convenient liquid formulation
  • INN-329 entering Phase 3 for magnetic resonance cholangiopancreatography (MRCP)